Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)

• Company Description    Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $15.41 Daily Weekly Monthly 20 Day Moving Average: 62,619 shares Shares Outstanding: 8.16 (millions) Market Capitalization: $125.81 (millions) Beta: 1.25 52 Week High: $23.91 52 Week Low: $8.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.93% -7.90% 12 Week 17.01% 8.43% Year To Date 14.74% 41.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1055 Westlakes Drive Suite 300 - Berwyn,PA 19312 USA ph: 610-727-3913 fax: - kgardner@lifesciadvisors.com http://www.annovisbio.com

• General Corporate Information    Officers Maria Maccecchini - President and Chief Executive Officer Michael Hoffman - Chairman of the Board and Director Jeffrey McGroarty - Chief Financial Officer Claudine Bruck - Director Reid McCarthy - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03615A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/22 Next Expected EPS Date: 04/05/23 Share - Related Items Shares Outstanding: 8.16 Most Recent Split Date: (:1) Beta: 1.25 Market Capitalization: $125.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.92 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/05/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -165.71% vs. Previous Quarter: 13.08% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - - 12/31/22 - -74.21 09/30/22 - -55.56 ROA 03/31/23 - - 12/31/22 - -71.12 09/30/22 - -53.90 Current Ratio 03/31/23 - - 12/31/22 - 12.86 09/30/22 - 28.12 Quick Ratio 03/31/23 - - 12/31/22 - 12.86 09/30/22 - 28.12 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - - 12/31/22 - 3.67 09/30/22 - 4.31 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - - 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©